Sanofi is pulling its PCSK9 drug Praluent from the Chinese market. President Donald Trump said U.S. pharmaceutical tariffs ...

The updated label no longer requires Leqvio (inclisiran) to be used in combination with statins for low-density lipoprotein ...

The US Food and Drug Administration approved the revised label for inclisiran, a small interfering RNA that reduces the ...

The US Food and Drug Administration (FDA) has approved a label update for Swiss pharma giant Novartis’ Leqvio (inclisiran), ...

AstraZeneca plans to spend $50 billion to expand manufacturing and research capabilities in the U.S. by 2030, it said on ...

The FDA has approved inclisiran (Leqvio) for first-line use in lowering LDL cholesterol, even without combining it with ...

The primary safety risks associated with gene therapy include immune reactions and off-target effects in unintended organs, ...

The FDA has approved a labeling update for Leqvio (inclisiran) allowing for first-line use in the treatment of hypercholesterolemia.

CRISPR gene editing shows potential for treating genetic diseases. Explore how it may impact Down syndrome treatment and ...

Verve Therapeutics has started dosing patients in a phase 1b trial of its in vivo gene-editing drug for high cholesterol, designed to permanently switch off the PCSK9 gene with a one-shot ...

While Rosie O’Donnell, 63, made a name for herself as a Broadway star and host of the Emmy-winning talk show The Rosie O’Donnell Show, she’s recently been garnering attention for her weight loss. And ...

Targeted rewriting of the epigenome promises to overcome several challenges in direct gene editing in patient therapies.